Pharmaceuticals
WeightWatchers to offer Novo Nordisk’s Wegovy pill after 2026 launch
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images WeightWatchers’ CEO said on Wednesday it plans to offer Novo Nordisk’s much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker. The […]
Read More
Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal
Every step is a struggle for Bruce Zimmerman, whose health has been deteriorating since he was diagnosed with multiple sclerosis eight years ago. In 2019, Zimmerman said, his then-employer offered him an opportunity that sounded irresistible: He and his wife, Becky, could take all-expense-paid trips to the Cayman Islands and the Bahamas to retrieve the medication […]
Read More
Novo Nordisk walked away from a $10 billion biotech deal — and investors aren’t sure if that’s smart or scary
Novo Nordisk has a lot on its plate — and it may not all be healthy. The pharmaceutical giant pulled out of its bidding war against rival Pfizer for clinical-stage biotech Metsera when the U.S. juggernaut matched its latest offer. Metsera accepted Pfizer’s $10 billion deal — significantly more than what Pfizer had initially offered […]
Read More
Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle
Smith Collection | Archive Photos | Getty Images Obesity drug developer Metsera said on Friday that it had accepted Pfizer‘s $10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and rival Novo Nordisk that erupted over the last week. Pfizer had appeared to have […]
Read More
Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk
US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. 6, 2025. Andrew Caballero-Reynolds | AFP | Getty Images President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in how many people can access […]
Read More
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows
The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows […]
Read More
Here’s how much weight loss drugs could cost you under Trump’s deals with Eli Lilly, Novo Nordisk
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popular injections and […]
Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming […]
Read More
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients […]
Read More
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
A box of Ozempic sits on a table in North Tyneside, Britain, Oct. 31, 2023. Lee Smith | Reuters Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market. Net profit for the […]
Read More